Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection

Cancer Research

Volumn 67, Issue 5, 2007, Pages 2226-2238

  Huang, Fei ^a   Reeves, Karen ^a   Han, Xia ^a   Fairchild, Craig ^a   Platero, Suso ^a   Wong, Tai W ^a   Lee, Francis ^a   Shaw, Peter ^a,b   Clark, Edwin ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PROGESTERONE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC MODEL; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; PATIENT SELECTION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; MODELS, GENETIC; PATIENT SELECTION; PROGNOSIS; PYRIMIDINES; THIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 33947225176     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3633     Document Type: Article

References (49)

1. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
4. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005;11:1226-36.
5. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
6. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
7. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application. J Clin Oncol 2005;23:7350-60.
8. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98:11462-7.
9. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
10. Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23:422-31.
11. Dressman HK, Hans C, Bild A, et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006;12:819-26.
12. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
13. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-44.
14. Verbeek BS, Vroom TM, Adriaansen-Slot SS, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996;180:383-8.
15. Myoui A, Nishimura R, Williams PJ, et al. C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-33.
16. Susva M, Missbach M, Green J. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol Sci 2000;21:489-95.
17. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003;9:2043-59.
18. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
19. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9.
20. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-32.
21. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel abl kinase inhibitor. Science 2004;305:399-401.
22. Doggrell SA. BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin Investig Drugs 2005;14:89-91.
23. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 2005;102:3395-400.
24. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
25. Finn RS, Dering J, Wilson CA, et al. Biologic effects and identification of predictive markers of response to Dasatinib (BMS-354825), novel, oral, multi-targeted kinase inhibitor in human breast cancer cell lines in vitro. Clin Cancer Res 2005;11:9022s.
26. Riss TL, Moravec RA. Comparison of MTT, XTT, and a novel tetrazolium compound for MTS for in vitro proliferation and chemosensitivity assays. Mol Biol Cell 1992;3:184a.
27. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
28. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001;98:10787-92.
29. Pawitan Y, Bjöhle J, Amler L, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy - derived and validated in two population based cohorts. Breast Cancer Res 2005;7:R953-64.
30. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
31. Yamanashi Y, Fukushige SI, Semba K, et al. The yes-related cellular gene lyn encodes a possible tyrosine kinase similar to p56(lck). Mol Cell Biol 1987;7:237-43.
32. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996;1287:121-49.
33. Duxbury MS, Ito H, Ashley SW, Whang EE. CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells. J Biol Chem 2004;279:23176-82.
34. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-32.
35. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609.
36. Mao W, Irby R, Coppola D, et al. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 1997;15:3083-90.
37. Brscardi JS, Tice DA, Parson SJ. C-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 1999;76:61-119.
38. Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 2005;9:1179-87.
39. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
40. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9.
41. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J. Robert J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 2004;64:356-62.
42. Peters D, Freund J, Robert L. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 2005;4:1605-16.
43. Roberts D, Schick J, Conway S, et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 2005;92:1149-58.
44. Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003;63:8791-812.
45. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein τ : a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005;102:8315-20.
46. Jain A, Tindell CA, Laux I, et al. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A 2005;102:11858-63.
47. Elicieri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915-24.
48. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004;167:223-9.
49. Horne WC, Sanjay A, Bruzzaniti A, Baron R. The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol Rev 2005;208:106-25.